SpeediCath Standard

K180258 · Coloplast · GBM · Oct 25, 2018 · Gastroenterology, Urology

Device Facts

• Record ID: K180258
• Device Name: SpeediCath Standard
• Applicant: Coloplast
• Product Code: GBM · Gastroenterology, Urology
• Decision Date: Oct 25, 2018
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 876.5130
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

Urinary catheter for intermittent use. The catheter is indicated for use by patients with chronic urine retention and patients with a post void residual volume (PVR) due to neurogenic and non-neurogenic voiding dysfunction. The catheter is inserted into the urethra to reach the bladder allowing the urine to drain.

Device Story

SpeediCath Standard is a sterile, single-use, hydrophilic-coated polyurethane urinary catheter. Device is pre-lubricated in a swelling media, packed, and sealed in a foil pouch. Used for intermittent catheterization to drain urine from the bladder in patients with voiding dysfunction. Operated by patients or healthcare providers. Insertion into the urethra allows urine drainage, relieving retention and managing PVR. Benefits include ease of use and reduced risk of trauma due to hydrophilic coating.

Clinical Evidence

Bench testing only. Biocompatibility per ISO 10993-1:2009; friction testing per ASTM D1894:2014; shelf-life testing per ASTM F1980-16; sterilization validation per ISO 11137-2:2013. All tests met pre-determined acceptance criteria.

Technological Characteristics

Hydrophilic-coated polyurethane catheter. Sterile, single-use. Lubricated via swelling media. Packaged in foil pouch. Sterilized per ISO 11137-2:2013. Complies with ASTM D1894:2014 (friction) and ASTM F1980-16 (shelf life).

Indications for Use

Indicated for patients with chronic urine retention and post void residual volume (PVR) due to neurogenic or non-neurogenic voiding dysfunction requiring intermittent urinary catheterization.

Regulatory Classification

Identification

A urological catheter and accessories is a flexible tubular device that is inserted through the urethra and used to pass fluids to or from the urinary tract. This generic type of device includes radiopaque urological catheters, ureteral catheters, urethral catheters, coudé catheters, balloon retention type catheters, straight catheters, upper urinary tract catheters, double lumen female urethrographic catheters, disposable ureteral catheters, male urethrographic catheters, and urological catheter accessories including ureteral catheter stylets, ureteral catheter adapters, ureteral catheter holders, ureteral catheter stylets, ureteral catheterization trays, and the gastro-urological irrigation tray (for urological use).

Predicate Devices

• SpeediCath (K023254)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

October 25, 2018

Coloplast Troy Thome Senior Regulatory Affairs Specialist 1601 West River Road North Minneapolis, Minnesota 55411

Re: K180258

> Trade/Device Name: SpeediCath Standard Regulation Number: 21 CFR 876.5130 Regulation Name: Urological catheter and accessories Regulatory Class: Class II Product Code: GBM Dated: September 21, 2018 Received: September 24, 2018

Dear Troy Thome:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You mav, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be avare that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

{1}------------------------------------------------

requirements, including, but not limited to: registration and listing (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely.

# Glenn B. Bell -S

for

Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

### Indications for Use

510(k) Number (if known) K180258

Device Name SpeediCath Standard

Indications for Use (Describe)

Urinary catheter for intermittent use.

The catheter is indicated for use by patients with chronic urine retents with a post void residual volume (PVR) due to neurogenic and non-neurogenic voiding dysfunction. The catheter is inserted into the ureach the bladder allowing the urine to drain.

Type of Use (Select one or both, as applicable)

| <div> <span> </span> Prescription Use (Part 21 CFR 801 Subpart D) </div> |
|---------------------------------------------------------------------------------|
| <div> <span> </span> Over-The-Counter Use (21 CFR 801 Subpart C) </div> |

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

## SpeediCath Standard 510(k) Summary

| Submitted by: | Coloplast Corp<br>1601 West River Road North<br>Minneapolis, MN 55411 USA |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Troy Thome<br>Coloplast Corp<br>Phone : [phone]<br>Fax : [phone]<br>Email : [e-mail] |
| Date of Summary: | October 24, 2018 |
| Trade or Proprietary Name: | SpeediCath® Standard |
| Common or Usual Name: | Catheter, urethral |
| Classification Name: | Urological catheter and accessories<br>21CFR 876.5130 |
| Classification: | Class II |
| Product Code: | GBM |
| Predicate Device: | SpeediCath, K023254 (Manufacturer: Coloplast) |
| Device Description: | The SpeediCath Standard is a sterile single use hydrophilic coated<br>polyurethane catheter. The catheter is placed in a swelling media,<br>packed and sealed in a foil pouch and sterilized. |
| Indication for Use: | Urinary catheter for intermittent use.<br>The catheter is indicated for use by patients with chronic urine retention<br>and patients with a post void residual volume (PVR) due to neurogenic<br>and non-neurogenic voiding dysfunction. The catheter is inserted into<br>the urethra to reach the bladder allowing the urine to drain. |
| Technological Characteristics: | The subject device has the same indications for use, design, materials<br>(with exception of the swelling media that lubricates the catheter) and<br>principles of operations as the predicate device. The subject device<br>includes the same coating and packaging configuration. |

{4}------------------------------------------------

Summary of Non-Clinical Testing:

Performance testing for SpeediCath Standard was conducted according to applicable sections of voluntary standards:

- . Biocompatibility testing according to ISO 10993-1:2009 and FDA Guidance "Use of International Standard ISO 10993-1" (2016) was completed.
- Bench testing was completed per ASTM D1894:2014 and . internal test methods.
- . Accelerated Aged (in compliance with ASTM F1980-16) shelf life testing was completed.
- . Sterilization dose confirmation was completed according to ISO 11137-2: 2013.

All tests met the pre-determined acceptance criteria.

The SpeediCath Standard is as safe and effective and is substantially equivalent to the legally marketed predicate device as demonstrated by the same intended use, same principles of operation, similar technological characteristics and performance data, and does not raise different questions of safety and effectiveness.

Substantial Equivalence Conclusion: